Is There a Third-Line Therapy for Metastatic Colorectal Cancer?

Seminars in Oncology

Volumn 33, Issue SUPPL. 11, 2006, Pages 36-38

  Grothey, Axel ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; MITOMYCIN C; OXALIPLATIN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE COURSE; DISEASE FREE INTERVAL; HUMAN; METASTASIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 33845415637     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.10.007     Document Type: Article

References (8)

1. Pitot H.C., Rowland K.M., Sargent D.J., et al. N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. Proc Am Soc Clin Oncol 24 (2005) 3506A (abstr)
2. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
3. Hedrick E.E., Hurwitz H., Sarkar S., et al. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 23 (2004) 249 (abstr 3517)
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
5. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
6. Saltz L.B., Lenz H., Hochster H., et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 24 (2005) 3508A (abstr)
7. Chen H., Mooney M., Boron M., et al. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). Proc Am Soc Clin Oncol 23 (2004) 249 (abstr 3515)
8. Hoff P.M., Pazdur R., Lassere Y., et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 22 (2004) 2078-2083